Due to health issues, this site is no longer maintained and will be shut down shortly.

EPGNY Epigenomics AG Sponsored ADRs

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. This is an ADR of a company whose stock trades outside of the U.S. as the symbol GF:ECX.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$9.56    OTCQX
As of 12/30/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Unknown
Industry:  Diagnostics & Research
Index country:  Germany
Country of incorporation:  Germany
IPO date:  07/10/2013
Outstanding shares:  818,562
Average volume:  0
Market cap:   $1,956,363
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy